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gained. RESULTS: Patients were categorized into 5FU/LV (n = 2,834), oxaliplatin 
based (n = 621), and irinotecan based (n = 945) subgroups, based on the regimen they 
received. The median improvement in overall survival with 5FU/LV, irinotecan or 
oxaliplatin based combination therapy was 1.25, 1.34, and 1.72 life-years, respec-
tively. The incremental cost with irinotecan or oxaliplatin based combination therapy 
compared with 5FU/LV was $205,837 and $93,651, respectively. When comparing 
to irinotecan based combination therapy, the incremental cost-effectiveness ratio 
of oxaliplatin based combination therapy was $67,637 per life-year gained. 
CONCLUSIONS: This analysis suggests that oxaliplatin or irinotecan based combina-
tion therapy improves overall survival but also substantially increases direct medical 
costs compared with 5FU/LV when used in elderly US patients with stage IV colon 
cancer. Oxaliplatin-based regimens are more cost-effective than irinotecan based 
regimens.
PCN61
THE COST-EFFECTIVENESS OF CETUXIMAB USE AMONG ELDERLY 
METASTATIC COLORECTAL CANCER PATIENTS
Wei DB, Lin CC
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: The cost-effectiveness of cetuximab has been controversial mainly 
because of its marginal clinical beneﬁts at very high medication cost. This study 
examines the cost-effectiveness of cetuximab versus best supportive care in the patients 
with metastatic colorectal cancer in US from the perspective of Medicare. METHODS: 
As modeled in a decision tree, three treatment options (cetuximab, cetuximab plus 
irinotecan, and best supportive care) are evaluated clinically and economically. Costs 
of cetuximab treatment options are largely determined by the treatment responses: 
complete or partial responsive, stable disease, or progressive, and whether or not the 
patient experienced severe infusion reaction and/or severe adverse events. The primary 
outcome is quality-adjusted life expectancy. The treatment response rates and quality 
of life measurements are based on the results from clinical trials. Incremental cost-
effectiveness ratios (ICER) between cetuximab treatments and best supportive care are 
presented to demonstrate the value of cetuximab treatments. Finally, sensitivity analy-
ses are conduct to test the robustness of the results. RESULTS: In the patients with 
metastatic colorectal caner, the incremental cost per quality-adjusted life year (QALY) 
was $336,218 for cetuximab, and $318,609 for cetuximab plus irinotecan, in com-
parison with best supportive care. One-way sensitivity analyses showed that the cost 
of cetuximab had the highest impact on ICERs, compared to other costs and quality 
of life parameters. Probabilistic sensitivity analyses by Monte Carlo simulation dem-
onstrated that best supportive care is more cost-effective than cetuximab treatments 
until the threshold of willingness to pay is raised up to $240,000. CONCLUSIONS: 
Our analyses suggest that cetuximab is not cost-effective, either in monotherapy or in 
combination with irinotecan, as the cost-effectiveness ratios are far beyond the 
accepted threshold of $50,000 per QALY gained. Cetuximab treatments need to be 
carefully evaluated before being delivered to metastatic colorectal cancer patients.
PCN62
COST EFFECTIVENESS OF RADICAL PROSTATECTOMY VERSUS 
WATCHFUL WAITING FOR NON-SCREEN DETECTED PROSTATE 
CANCER: EXTRAPOLATING FROM THE SCANDINAVIAN TRIAL
Shteynshlyuger A
Washington University School of Medicine, St. Louis, MO, USA
OBJECTIVES: The beneﬁt of screening for and deﬁnitive treatment for prostate cancer 
has been questioned. Results from the Scandinavian study of radical prostatectomy 
compared to watchful waiting for non-screen detected prostate cancer demonstrated 
decrease in prostate cancer speciﬁc mortality, palliative treatment and overall survival. 
We evaluated the cost effectiveness of radical prostatectomy compared to watchful 
waiting using data from the Scandinavian study protocol when extrapolated to the 
US. METHODS: We used the previously reported cost of care data for patients with 
prostate cancer based on the patterns of care observed in the CaPSURE database. The 
data from the Scandinavian trial, in accordance with the study protocol, was used to 
determine the costs and cost-effectiveness of radical prostatectomy for treatment of 
prostate cancer. The cost-effectiveness for radical prostatectomy was determined and 
was adjusted for the costs of androgen deprivation therapy as used in each study arm. 
A model incorporating age at diagnosis, life expectancy and estimate of beneﬁts from 
radical prostatectomy was created that predicts cost effectiveness of surgical interven-
tion for prostate cancer. A sensitivity analysis was performed to test the robustness 
of results. RESULTS: Compared to watchful waiting, radical prostatectomy is associ-
ated with savings of $92,259 per life saved or $4,128 per LYS. When the rate of 
treatment with ADT in each study arm is taken into account, radical prostatectomy 
for treatment of non-screen detected prostate cancer is associated with cost savings of 
$475,297 per life saved or savings of $27,959 per life-year saved compared to the 
costs of watchful waiting. CONCLUSIONS: Radical prostatectomy is a cost effective 
treatment for non-screen detected prostate cancer. Treatment with radical prostatec-
tomy is associated with signiﬁcant cost savings, improved survival, decreased rate of 
metastatic disease and lower rate of palliative care compared to watchful waiting. For 
patients who are surgical candidates watchful waiting is associated with higher mor-
bidity, mortality and costs.
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OBJECTIVES: Compare cost-effectiveness of three non-melanoma skin cancer 
(NMSC) strategies: all Mohs Micrographic Surgery (MMS), all surgical excision and 
mixed MMS and excision. METHODS: A decision-analytic model compared strate-
gies using data from a prospective sample (n = 540) treated with MMS or excision at 
a university-afﬁliated dermatology clinic from 1999–2000. The newest (2007) Medi-
care costing rules with tumor size, location and number of stages for MMS were used. 
Total cost included the procedure, pathology, drugs, 2 month follow-up visits, second-
ary procedures, repairs or grafts and recurrences. Short Form (SF)-12 and Skindex 
scores at baseline and 2 years were mapped to the Health Utility Index (HUI) to adjust 
life expectancy and recurrence, our major outcomes. Cost per quality adjusted life 
year saved (QALYS) was the ﬁnal outcome. Sensitivity analysis tested uncertainty of 
model parameters. RESULTS: The all MMS strategy was most cost-effective when 
compared to mixed (ICER = $30,521/QALYS) and all excision strategies (ICER = 
$6,722/QALYS). The mixed strategy was cost-effective compared to the all excision 
strategy (ICER = $1,924/QALYS). All excision was least costly ($1634.50/patient), 
mixed next ($1681.00/patient) and all MMS was most costly ($1830.10/patient). The 
all MMS strategy (17.2081 QALYS) was most effective compared to mixed (17.2032 
QALYS) and all excision (17.1790 QALYS) strategies. The model is sensitive to the 
proportion of patients who receive MMS versus excision in the mixed strategy. The 
all MMS strategy no longer is cost-effective compared to the mixed strategy when the 
MMS proportion is decreased from 58.8% to 50% (ICER = $2,793,794) and at 45% 
the mixed strategy dominates all other strategies. Not until $900 is added to procedure 
cost for MMS, does the all MMS strategy lose its cost-effectiveness. CONCLUSIONS: 
All MMS for NMSC is the most cost-effective strategy although the mixed strategy is 
preferred in some mixtures of patient populations. This analysis demonstrates that 
MMS is cost-effective if clinically indicated.
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OBJECTIVES: Sorafenib is the only agent that has proven to improve survival in 
AHCC (Llovet, NEJM 2008), and has been considered cost-effective in Canada 
(Muszbek, Curr Med Res Opin 2008), when compared with BSC. In clinical practice 
in Brazil, however, patients with AHCC with no access to sorafenib are often treated 
with other systemic agents, none of which are able to improve the outcome. The objec-
tive of this study was to evaluate the cost-effectiveness of sorafenib+BSC vs BSC alone 
in Brazil, from the perspective of the public health-care system. METHODS: A Markov 
model was developed to project the lifetime survival and costs for both interventions 
using data from the TTP and OS Kaplan-Meier curves from SHARP trial using a log-
normal distribution and an ad hoc panel with Brazilian medical oncologists, hepatolo-
gists, and liver surgeons. Treatment effectiveness was measured in life-years gained 
(LYG). Resource utilization included drug, administration, physician visits, monitor-
ing, and adverse events. Costs (in R$, with R$ 1.00 ∼ US$ 0.58) and survival beneﬁts 
were discounted annually at 5%. Univariate and probabilistic sensitivity analyses were 
conducted. RESULTS: Lifetime per-patient costs in R$ (US$) were 76,032 (43,447) and 
9,776 (5,586) for sorafenib+BSC and BSC alone, respectively. Sorafenib drug cost 
accounted for nearly 79% of treatment costs. The incremental survival beneﬁt with 
sorafenib+BSC was 0.49 life-years. The incremental cost-effectiveness ratio of 
sorafenib+BSC vs BSC alone was R$ 135,262 (US$ 77,293) per LYG. Variations in the 
lognormal parameters for OS of both alternatives demonstrated to be the most inﬂu-
ential variables in the cost-effectiveness result in the deterministic sensitivity analysis. 
CONCLUSIONS: The addition of sorafenib to BSC is the only intervention that has 
been found to improve survival in AHCC and the cost-effectiveness results should be 
interpreted considering the low cost and inefﬁciency of the comparator.
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OBJECTIVES: Multiple myeloma (MM) is a hematologic malignancy mainly affecting 
the elderly population. It is incurable and patients experience a considerable reduction 
of health-related-quality-of-life (HRQoL). Some newer therapies have shown better 
clinical effects but are more costly. Pharmacoeconomic studies on MM have been 
widely conducted overseas but local data was lacking. This study aimed to examine 
the cost-effectiveness of the treatments for MM in Macao, China. METHODS: A 
retrospective cost-effectiveness study with HRQoL assessment was conducted. Forty 
patients from the largest public hospital in Macao from 1997–2007 with conﬁrmed 
MM were studied. Data for costs and treatment effects were extracted from patients’ 
